Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | QDPR | P09417 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1132378 | 0.98 | GNAI3 (0.50) | CYP1A2TDP1GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL16397180 | 0.95 | GNAI3 (0.49) | CYP1A2TDP1GNAI3GNAO1GNAI1 | |
| SCHEMBL14275857 | 0.91 | EPHX2 (0.46) | CYP1A2TDP1GNAI3GNAO1GNAI1 | |
| SCHEMBL17284621 | 0.88 | CHRM1 (0.44) | CYP1A2TDP1GNAI3GNAO1GNAI1 | |
| Trifluoroacetic Acid SCHEMBL23535368 | 0.86 | DPP7 (0.41) | GNAI3GNAO1GNAI1EPHX2EPHX1 | |
| SCHEMBL1588131 | 0.86 | — | — | |
| SCHEMBL2603683 | 0.86 | — | — | |
| SCHEMBL69055 | 0.86 | — | — | |
| SCHEMBL28836025 | 0.84 | TP53 (0.46) | GNAI3GNAO1GNAI1EPHX2EPHX1 | |
| Hydrochloric Acid SCHEMBL18228312 | 0.84 | GNAI3 (0.43) | CYP1A2TDP1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 990 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036730-A | Gαq/11 protein inhibitor with purine skeleton, and preparation method and application thereof | 中山大学 | 2026-05-15 | — | — | CN | claimed |
| CN-114728009-A | Preventing or treating diseases and disorders associated with tissue damage | 李晓祥 | 2022-07-08 | — | — | CN | claimed |
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2021-04-13 | — | — | US | claimed |
| WO-2021024141-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | LI XIAOXIANG (CN) | 2021-02-11 | — | — | WO | claimed |
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | Amcure Biosciences Pte. Ltd. (SG) | 2020-06-04 | — | — | US | claimed |
| EP-3647313-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Xiamen University (CN) | 2020-05-06 | — | — | EP | claimed |
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-04-23 | — | — | US | claimed |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd . (CN) | 2020-04-16 | — | — | US | claimed |
| EP-3626718-A1 | FIVE- AND SIX-MEMBERED AZA-AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATION | Xiamen University (CN) | 2020-03-25 | — | — | EP | claimed |
| CN-110869369-A | Five-membered and six-membered nitrogen heteroaromatic ring compound, preparation method thereof, medicinal composition and application thereof | 厦门大学 | 2020-03-06 | — | — | CN | claimed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | claimed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | claimed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | claimed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | claimed |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | claimed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | claimed |
| JP-2005514365-A | — | — | 2005-05-19 | — | — | JP | claimed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | claimed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | claimed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076005-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | CYP1A2 4144/4885TDP1 794/4885GNAI3 598/4885 |
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CYP4A11, CYP2D6, CYP3A43 | CYP1A2 29/4885TDP1 3875/4885GNAI3 962/4885 |
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | MST1, STK11, MSTN | CYP1A2 3956/4885TDP1 258/4885GNAI3 2615/4885 |
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | KRAS, NRAS, RASSF5 | CYP1A2 2132/4885TDP1 4613/4885GNAI3 238/4885 |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | MST1, STK11, MSTN | CYP1A2 3956/4885TDP1 258/4885GNAI3 2615/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | CYP1A2 215/4885TDP1 1138/4885GNAI3 1353/4885 |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | CYP1A2 1977/4885TDP1 3230/4885GNAI3 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.